AbbVie (ABBV) Total Non-Current Liabilities (2012 - 2026)

AbbVie (ABBV) has reported Total Non-Current Liabilities for 15 consecutive years, with $106.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 5.52% year-over-year to $106.4 billion in Q2 2026; TTM through Jun 2026 was $106.4 billion, a 5.52% decrease from a year earlier, with the FY2025 full-year figure at $104.7 billion, down 4.97% from the prior year.
• Total Non-Current Liabilities was $106.4 billion for Q2 2026 at AbbVie, down from $109.0 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $120.7 billion in Q1 2024 and troughed at $103.3 billion in Q1 2023.
• A 5-year average of $109.4 billion and a median of $109.5 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities slipped 9.53% in 2022 and advanced 16.8% in 2024, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $105.1 billion in 2022, then slipped by 0.68% to $104.4 billion in 2023, then rose by 5.47% to $110.1 billion in 2024, then declined by 4.97% to $104.7 billion in 2025, then climbed by 1.71% to $106.4 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $106.4 billion (Q2 2026), $109.0 billion (Q1 2026), and $104.7 billion (Q4 2025), per Business Quant data.